ReposiTrak And SPAR Launch Touchless Retail: Professional Merchandising At Half The Traditional Cost

ReposiTrak, Inc. (TRAK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ReposiTrak Reports 16% Increase in Net Income 20% Increase in EPS, for Fourth Quarter of Fiscal 2026 Full-Year Net Income Up 8%; Full-Year Diluted EPS of $0.39; Company Returns $5.3 Million of Capital to Shareholders, Ends Year with $27.3 Million in Cash & No Bank De

SPAR Group, Inc. (SGRP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 For Immediate Release SPAR Group, Inc. Reports Second Quarter Fiscal 2026 Results Return to Profitability CHARLOTTE, NC, August 13, 2026 – SPAR Group, Inc. (OTCQB: SGRP) (“SGRP”, and together with its subsidiaries, “SPAR,” “SPAR Group” or the “Company”), an innovativ

SPAR Group reported full-year 2025 net revenue of $136.1 million, up 3.3%, with U.S. revenue at $122.1 million (+3.9%) and Canada flat at $14.1 million. Gross profit fell to $21.7 million (15.9% margin). The company posted a net loss of $24.6 million ($1.04/share) and adjusted net loss of $10.7 million ($0.45/share). It completed exiting non–U.S./Canada joint ventures, launched a ReposiTrak AI partnership, and guided 2026 revenue to $143–$151 million with gross margin of 20.5%–22.5%.

Evaxion A/S (NASDAQ: EVAX) presented phase 2 trial data for its personalized cancer vaccine EVX-01, showing strong immune responses in advanced melanoma patients. The data, shared at the SITC 2026 Annual Meeting, includes 89% vaccine target precision and sustained T-cell responses. Evaxion's AI-Immunology platform demonstrated strong predictive performance, with significant association between predictions and actual T-cell responses.

Uber aims to have 700 robotaxis by year-end, expanding to 2,000 by 2027. The company will launch driverless vehicles in Las Vegas with Zoox and Motional. Uber plans to invest over $10 billion in robotaxis, partnering with Lucid and Rivian for vehicle supply. Driverless testing with Nuro and Lucid will start this quarter, with commercial service beginning in early 2024 in the San Francisco Bay Area and Houston.

HCW Biologics (NASDAQ:HCWB) presented data on its cancer therapy HCW11-040 at the Society for Immunotherapy of Cancer's annual meeting. The therapy showed comparable blocking activity to pembrolizumab and outperformed it in rejuvenating exhausted T cells. HCW11-050, its mouse homologue, demonstrated anti-solid-tumor activities. The company focuses on developing fusion immunotherapeutics for chronic inflammation-related diseases.